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ABSTRACT
Mesenchymal Stem Cells (MSCs) are effective therapeutic agents enhancing the repair of injured
tissues mostly through their paracrine activity. Increasing evidences show that besides the secre-
tion of soluble molecules, the release of extracellular vesicles (EVs) represents an alternative mech-
anism adopted by MSCs. Since macrophages are essential contributors toward the resolution of
inflammation, which has emerged as a finely orchestrated process, the aim of the present study
was to carry out a detailed characterization of EVs released by human adipose derived-MSCs to
investigate their involvement as modulators of MSC anti-inflammatory effects inducing macro-
phage polarization. The EV-isolation method was based on repeated ultracentrifugations of the
medium conditioned by MSC exposed to normoxic or hypoxic conditions (EVNormo and EVHypo).
Both types of EVs were efficiently internalized by responding bone marrow-derived macrophages,
eliciting their switch from a M1 to a M2 phenotype. In vivo, following cardiotoxin-induced skeletal
muscle damage, EVNormo and EVHypo interacted with macrophages recruited during the initial
inflammatory response. In injured and EV-treated muscles, a downregulation of IL6 and the early
marker of innate and classical activation Nos2 were concurrent to a significant upregulation of
Arg1 and Ym1, late markers of alternative activation, as well as an increased percentage of infil-
trating CD206pos cells. These effects, accompanied by an accelerated expression of the myogenic
markers Pax7, MyoD, and eMyhc, were even greater following EVHypo administration. Collectively,
these data indicate that MSC-EVs possess effective anti-inflammatory properties, making them
potential therapeutic agents more handy and safe than MSCs. Oc STEM CELLS TRANSLATIONAL
MEDICINE 2017;00:000–000
SIGNIFICANCE STATEMENT
The rational control of inflammation, a universal response to injury, is a good candidate for trig-
gering tissue repair. Mesenchymal stem cell (MSC) paracrine activity favors tissue repair modu-
lating inflammation-associated immune cells. An alternative approach to regulate the
inflammatory response is here proposed. This strategy relies on the use of extracellular vesicles
(EVs) derived from human adipose tissue-derived MSCs as mediators of the anti-inflammatory
effects, switching macrophages into an alternative activation profile. Despite the remaining chal-
lenges, these results highlight the importance of EVs as a handy cell-free approach guiding
regenerative processes.
INTRODUCTION
Tissue repair, sometimes called healing, refers to
the restoration of tissue architecture and function
after an injury [1]. It is a multistep, dynamic pro-
cess and consists of three consecutive and over-
lapping stages: inflammation, new tissue
formation, and remodeling [2]. The transition
from one stage to another is controlled and regu-
lated by cell-released mediators, which are
common to most regenerating tissues, with excep-
tion of some specialized ones, such as liver and
skeletal tissues, that possess distinctive forms of
regeneration and follow separate pathways [3].
There is an increasing evidence that the inflamma-
tory microenvironment resulting from the initial
cell interactions dictates how the healing process
will proceed [4]. In particular, innate immune cells,
such as macrophages, lead the inflammatory cas-
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TISSUE ENGINEERING AND REGENERATIVE MEDICINE
at injury sites [5, 6]. Diversity and plasticity are distinctive character-
istics of macrophages. Classical M1 and alternative M2 activated
macrophages represent two extremes of a dynamic state of activa-
tion. M1 macrophages exhibit potent antimicrobial properties, high
capacity to present antigen, and consequent activation of Th1
responses. Conversely, M2 macrophages possess the capacity to
facilitate tissue repair and regeneration [7].
The contribution of mesenchymal stem cells (MSCs) in tissue
repair has been addressed in a variety of disease models [8, 9]. Con-
textually, their efficacy in the functional improvement of injured tis-
sues was mostly related to a paracrine effect rather than a direct
engraftment and differentiation [10–12]. We have recently demon-
strated that in an inflammatory environment as the one generated
during the early phases of thewound healing process,MSC paracrine
activity was significantly modulated promoting a functional switch of
macrophages from a pro- to an anti-inflammatory state, thus corrob-
orating evidences showing that the mobilization of innate immune
cells mediates the activation of regenerative processes [10, 13].
Among the factors responsible for the paracrine effects of
MSCs, extracellular vesicles (EVs) have been recently described as
new players in cell-to-cell communication by serving as vehicles
for transfer between cells of membrane and cytosolic proteins, lip-
ids, and genetic information [14, 15]. EVs are defined as a mixed
population of membrane-surrounded structures with overlapping
composition, density, and sizes, including exosomes, ectosomes,
microvesicle particles, and apoptotic bodies in accordance with
the recommendations of the International Society for Extracellular
Vesicles (ISEV) [16].
Recent studies demonstrated that EVs represent physiologi-
cally relevant and powerful components of the MSC secretome,
playing important roles in local induction of tissue regeneration
[8, 12, 17]. In the present study, we focused on the detailed char-
acterization of EVs released by human adipose tissue-MSCs to
evaluate if the crosstalk between MSCs and cells of the innate
immunity could be carried out by secreted EVs and if these inter-
actions occur also in a regenerative microenvironment as the one
generated following skeletal muscle damage. To mimic the typical
environment established during tissue injury, EVs were isolated
from the conditioned medium of MSCs harvested under both nor-
moxic and hypoxic culture conditions (EVNormo and EVHypo, respec-
tively). We here report that both types of vesicles acted as
mediators of the dynamic interplay between MSCs and cells of
the innate immunity in vitro and in vivo. EVs effectively triggered
the macrophage proliferation and polarization from a M1 to a M2
phenotype. Of note, the hypoxic preconditioning induced an
intensified release of EVs enriched with miRNAs involved in differ-
ent stages of the healing process. Taking advantage of a cardio-
toxin (CTX)-induced skeletal muscle injury model, we confirmed a
potent EV-mediated anti-inflammatory effect, through the signifi-
cant downregulation of the inflammatory cytokine IL6 accompa-
nied by the concomitant upregulation of IL10. At the same time
we observed also a downregulation of the M1 marker Nos2 and
an increased expression of the putative M2 markers Arg1 and
Ym1, together with an increased percentage of CD206pos cells infil-
trating damaged and EV-treated muscles.
MATERIALS AND METHODS
Mice
C57Bl/6 (MHC H2b haplotype) male mice between 3 and 5 month
old were used. All mice were bred and maintained at the Animal
Facility of “IRCCS Azienda Ospedaliera Universitaria San Martino –
IST, Istituto Nazionale per la Ricerca sul Cancro.” All animal proce-
dures were approved by the Local Ethical Committee and per-
formed in accordance with the national current regulations
regarding the protection of animals used for scientific purpose (D.
Lgs. 4 Marzo 2014, n. 26, legislative transposition of Directive
2010/63/EU of the European Parliament and of the Council of 22
September 2010 on the protection of animals used for scientific
purposes).
Adipose Tissue-Derived MSCs Isolation and Culture
Subcutaneous adipose tissue in the form of liposuction aspirates
was obtained from human healthy donors (n 5 18) during routine
lipoaspiration after informed consent. Protocol and procedures
were approved by the local ethical committee. For more details
regarding MSC isolation and characterization, see Supporting
Information Materials and Methods.
Bone Marrow-Derived Macrophage Isolation and
Culture
Bone marrow (BM)-derived macrophages (M/) were isolated
from C57Bl/6 mice by flushing the BM with 5 ml of Phosphate
Buffered Saline (PBS), as previously described [10]. Each primary
culture was obtained from the BM of 3 mice, and a total of 6 pri-
mary cultures were used. Details are in Supporting Information
Materials and Methods.
Preparation of MSC Conditioned Media and EV Isolation
EVs were isolated from the conditioned media derived from
human MSCs. When cells reached a confluence of 80%, extensive
washes in PBS were performed to remove any possible residue of
FBS. The cells were transferred in EV-isolation medium (serum-
free Dulbecco-Modified Eagle Medium (D-MEM) not supple-
mented with Fibroblast Growth Factor-2) and the culture split into
two subcultures maintained for 48 hours under normoxic (20%
O2) and hypoxic (1% O2) condition, respectively. EVs were isolated
from normoxic- and hypoxic-conditioned media (EVNormo and
EVHypo) by differential centrifugation at 300g for 10 minutes,
2,000g for 20 minutes, 10,000g for 30 minutes at 48C to eliminate
cells and debris. Obtained supernatants were depleted of residual
floating cells and cell debris by filtration with 0.22 lm filter units
(Merck Millipore Ltd, Vimodrone, MI, Italy), followed by two con-
secutive steps of ultracentrifugation at 100,000g for 90 minutes,
including a washing step in PBS, to precipitate EVs. A Beckman
Coulter ultracentrifuge (Beckman Coulter Optima L-90K ultracen-
trifuge; Beckman Coulter, Fullerton, CA) was used with swinging
bucket rotors type SW28 and SW41Ti. EVs were collected in 100
ll of filtered PBS and used immediately after isolation.
Transmission Electron Microscopy
The morphological evaluations of isolated EVNormo and EVHypo,
and corresponding MSC monolayers were performed by transmis-
sion electron microscopy (TEM). For details, see Supporting Infor-
mation Materials and Methods.
Protein Quantification and Immunoblot Analysis
Protein contents of isolated EVs were measured using a BCA pro-
tein assay kit (Thermo Scientific Pierce, Rockford, IL) following
manufacturer’s instructions. Sample preparation for immunoblot
analysis is described in Supporting Information Materials and
Methods.
2 MSC-Derived EVs Promote Macrophage Polarization
Oc 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
Cell Viability and BrdU Cell Proliferation Assay
3 3 104 M/ in serum free medium were plated in 96-well plates
for 24 hours in the presence or absence of either EVNormo or
EVHypo. Cell proliferation was measured with the use of the Cell
Proliferation Enzyme-linked immunosorbent assay (ELISA), Bromo-
deoxyuridine (BrdU) (Roche Mannheim, Germany), according to
the manufacturer’s instructions. Five independent experiments
were performed.
In vivo Angiogenic Assay
The in vivo angiogenic assay is described in Supporting Informa-
tion Materials and Methods.
Flow cytometry Analysis
At least nine independent preparations of both EVNormo and
EVHypo were stained with 10 lM Cell Trace (Molecular probes) in
combination with the mouse anti-human monoclonal antibody
(mAb) CD63 (Clone: H5C6) (BD Pharmingen) or the anti-human
mAb CD105 (Clone: SN6) (eBioscience). A set of microsphere sus-
pensions (1, 4 lm) (Molecular Probes) was used as size reference.
An unstained sample was acquired to detect the sample auto-
fluorescence and set the photomultiplier for all the three used
channels; fluorescent spill-over was controlled by spectral overlap
adjustment, acquiring single-color stained tubes. Forward and side
scatter channels (FSC and SSC) were used on a logarithmic scale
visualized in bi-exponential mode. The FSC and SSC photomulti-
pliers were set using background noise as the lower optical limit,
acquiring a sample of sterile PBS tube. The threshold, set on the
FSC channel, was regulated to reduce the noise progressively, allo-
cating dots in low left corner of plot, in order to clearly detect EVs.
Details about the absolute count of EVs, the immunophenotype of
M/ cultured in presence/absence of EVs and the immunopheno-
type of M/ infiltrating the injured tibialis anterior (TA) muscles
are reported in Supporting Information Materials and Methods.
RNA Extraction
RNA extraction procedure for both EV pellet and TA muscles is
described in Supporting Information Materials and Methods.
microRNA Profiling
The miRNA fraction of each sample was subjected to stem-loop
RT-qPCR amplification, as described in Supporting Information
Materials and Methods.
Quantitative Real-Time PCR
To validate the RNA sequencing data, we performed a qPCR analy-
sis of miR-199a-3p, miR-126, miR-223, and miR-146b. Each micro-
RNA was tested on three independent preparations of both
EVNormo and EVHypo, and three independent experiments were
performed. The miRNA-specific miScript Primer Assays were pur-
chased from QIAGEN (MS00007602 for miR-199a-3p, MS00003430
for miR-126, MS00003871 for miR-223, and MS00003542 for miR-
146b). Details reported in Supporting Information Materials and
Methods.
Details about the quantification of IL-6, IL-10, Nos2, Arg1,
Ym1, MCP1, eMyhc, Pax7, and MyoD mRNAs in TA muscles of CTX
and EVs injected mice are described in Supporting Information
Materials and Methods.
Labeling and Internalization of EVs
EVNormo and EVHypo (derived from three different MSC cultures)
were labeled using PKH67 membrane-binding fluorescent labels
according to manufacturer’s recommendations (Sigma-Aldrich,
Allentown, PA).
Three independent primary cultures of M/ seeded on glass
slides placed in 24-well plates were incubated at 378C with labeled
EVs at a concentration of 1 lg EVs/10,000 cells. Uptake was
stopped after 3 hours by washing and fixation in 4% paraformal-
dehyde for 20 minutes.
Immunofluorescence Analysis
Immunofluorescence analysis performed on M/ is included in
Supporting Information Materials and Methods.
Mouse Model of Cardiotoxin-Induced Muscle Injury
Eight-week-old male C57BL/6 mice (six per group) were anesthe-
tized with isoflurane. Twenty microliter of 10 mM cardiotoxin
(CTX) (Sigma) in PBS were intramuscularly administered into the
TA muscle of both legs. One microgram of EVs (diluted in 20 ll
PBS) derived from normoxic and hypoxic MSCs were injected into
the right and left TA muscles, respectively. Control mice were
treated with 20 ll of vehicle solution. EVs or vehicle solution were
injected 2 hours postadministration of CTX and a boost of EVs was
done 4 days after muscle injury. Mice were sacrificed after 1, 2,
and 7 days post lesion induction and the harvested TA muscles
were snap-frozen in liquid nitrogen before further RNA extraction
processing.
Histology and Morphometric Analysis
The histological analysis of differentially-treated muscle tissues is
described in Supporting Information Materials and Methods.
Statistical Analysis
All results were expressed as mean6 SD or as mean6 SEM from
at least three independent experiments. Statistical comparisons
between two groups were performed using an unpaired two-
tailed Student’s t test. Differences among multiple groups were
statistically analyzed employing One-way ANOVA and Tukey’s mul-
tiple comparisons test. A p value below.05 was considered to be
statistically significant. All statistical analyses were performed
using GraphPad Prism Version 6.0a (GraphPad Software, La Jolla,
CA).
RESULTS
Hypoxic Conditioning of MSCs Enhances the Release of
EVs Endowed With Angiogenic Potential
The cargo and function of EVs depend on their cells of origin, sug-
gesting that intercellular communication through vesicles is a
dynamic system, adapting its message depending on the condi-
tions of the producing cells [18]. Changes in oxygen concentra-
tions affect many of the distinctive characteristics of stem and
progenitor cells [19]. On this basis, we evaluated whether hypoxic
conditioning of human adipose tissue-derived MSCs could influ-
ence their EV secretion. Confluent primary MSC cultures fulfilling
the minimal criteria proposed by the International Society for Cel-
lular Therapy [20] (Supporting Information Fig. 1A) were main-
tained for 48 hours in serum-free medium in a normoxic or
hypoxic environment. After the starvation period, more than 85%
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of MSCs resulted viable in both culture conditions (Supporting
Information Fig. 1B). As expected, MSCs cultured in hypoxic condi-
tions had a higher level of HIF-1a expression than those cultured
in normoxic conditions (Supporting Information Fig. 1B). After 48
hours of medium conditioning, isolated EVNormo and EVHypo, and
corresponding MSC monolayers (MSCNormo and MSCHypo) were
analyzed by TEM. TEM revealed the presence of larger shedding
vesicles (microvesicles) as well as several multivesicular bodies
(MVBs) containing exosomes within the cell cytoplasm in both cul-
ture conditions, indicating the release of a mixed population of
EVs (Fig. 1A). In both samples, EVs appeared with a round-shape
morphology, mainly isolated or less frequently aggregated in small
groups. They showed a diameter ranging from 40 to 250 nm sug-
gesting that the separation procedure selected a population of
nano-scaled vesicles referable mostly but not only to exosomes.
No morphological differences between EVNormo and EVHypo were
observed with regard to their size, shape, or electrondensity (Fig.
1A). In order to characterize isolated EVs, immunoblot and flow
cytometry analysis were performed. Western blot analysis
revealed that both EVNormo and EVHypo express the specific vesicu-
lar protein CD81, member of the tetraspanin family, and Alix, that
is involved in MVB formation (Fig. 1B). EVNormo and EVHypo were
further characterized taking advantage of a multiparametric flow
cytometry approach. To separate true events from background
noise, EVs were defined as events that were included in the
dimensional gate of 1 lm, which was established according to a
well-defined light scatter profile of beads with absolute size (Fig.
1C). EVs were targeted with the Cell Trace labeling, in order to
consider only intact membrane structures, along with either the
mesenchymal marker CD105 or the vesicular marker CD63. Both
types of Cell Trace labeled-EVs expressed the CD105 and CD63 anti-
gens, but the percentage of EVs co-expressing CD63 was significantly
higher in the hypoxic condition compared to the normoxic one
(p< .01) (Fig. 1D).The absolute quantification of EVNormo and EVHypo
was determined by comparing their events to a known number of
fluorescent bead events (Trucount beads, Fig. 1C).The hypoxic condi-
tioning induced a significantly increased release of EVs when com-
pared to the normoxic condition (p 5 .0318) (Fig. 1E).
The observations that the regenerative properties mediated
by MSCs, including the ability to stimulate angiogenesis, are medi-
ated by EV secretion, and that hypoxia is a factor that favors the
accumulation of pro-angiogenic molecules [21], led us to explore
the angiogenic potency of MSC-EVs in vivo by performing the
Matrigel plug assay. After 3 weeks of implantation, we observed
that EVNormo and EVHypo induced the formation of vessel-like
endothelial structures (Fig. 1F). Matrigel plugs in presence of both
types of vesicles were enriched in angiogenic molecules, such as
Pecam1 and VegfA when compared with control empty plugs (Fig.
1G). The presence of vessels along the periphery of the plugs was
confirmed in all the experimental conditions by hematoxylin and
eosin and CD31 immunostaining (Fig. 1H). Noteworthy, in EV Hypo-
treated plugs, a higher expression of Pecam1 and VegfA and an
increased density of vessels with a larger diameter were detecta-
ble (Fig. 1G, 1H).
EVs Secreted Under Hypoxia Express miRNAs Actively
Involved in Different Stages of the Healing Process
miRNAs influence many biological processes and can be taken up
as EV cargo also by distant cells [22, 23]. To compare the profile of
miRNAs present in both EVNormo and EVHypo, each sample was
tested for the expression of 384 different miRNAs by PCR array. In
order to identify differentially expressed miRNAs in EVs released
under hypoxic conditions, raw data were normalized using the
small U6 RNA as endogenous reference. Setting EVNormo as control
sample and EVHypo as test sample, the fold change was calculated
dividing the normalized gene expression profile of the test sample
by the corresponding control sample. The hypoxic cell treatment
during the EV release induced the significant over-expression of
20 miRNAs and the under-expression of 48 miRNAs (Fig. 2A, 2B).
We focused on four specific miRNAs that are implicated in the
inflammatory (miR-223 and miR-146b) [24–26], proliferative and
differentiative phases (miR-126 and mir-199a) [27, 28] of the heal-
ing process (Fig. 2C–2F). The significantly upregulated expression
of these miRNAs was confirmed by quantitative Real-Time PCR,
thus suggesting that hypoxia-driven pathways are critical for suc-
cessful tissue repair.
MSC-Derived EVs Promote Macrophage Polarization
In the healing process, macrophages mediate the inflammatory
phase by maintaining a pro-inflammatory phenotype in order to
inhibit possible infections. However, they switch to a pro-
resolving, anti-inflammatory phenotype as soon as the initial
“emergency” is over [29, 30].
To evaluate the role exerted by EVs in macrophage polariza-
tion, we began characterizing the interactions of EVs with recipi-
ent cells. We tested whether BM-derived macrophages (M/)
were able to internalize both EVNormo and EVHypo. M/ that were
incubated for 3 hours in presence of either EVNormo or EVHypo pre-
viously stained with the fluorescent lipophilic membrane-diffuse
dye PKH67, efficiently internalized EVs within their cytoplasm (Fig.
3A). This result was also confirmed by flow cytometry analysis per-
formed after the coculture period on responding cells. More than
70% of EV-treated macrophages resulted positive for the expres-
sion of the FITC-fluorescent dye PKH67 used to stain EVs and no
FITC-positive signal was detectable in untreated macrophages
(Fig. 3B). Cell proliferation of recipient M/ maintained for 24
hours in serum free culture conditions was evaluated using a
BrdU-uptake assay. Macrophage proliferation was significantly
increased following treatment with both EVNormo and EVHypo com-
pared to untreated cells (p< .0001), and this increase was even
greater in hypoxic conditions compared to the normoxic
(p 5 .0011) (Fig. 3C).
The flow cytometric analysis of M/ maintained in standard
culture medium (M/ w/o EVs) or in the presence of either
EVNormo or EVHypo was performed. In standard conditions, M/
expressed statistically significant higher levels of the pro-
inflammatory M1-like markers Ly6C, CD11b, CD40, and CD86 com-
pared to the EV-treated cells (Ly6C: p 5 .0186; CD11b: p 5 .0017;
CD40: p 5 .0073; CD86: p 5 .0019) and did not express any of the
typical M2 markers, such as the scavenger receptor CD36, the
mannose receptor CD206 or the avb3 integrin CD51 (Fig. 3D, 3E).
Interestingly, 72 hours of treatment with both EVNormo and EVHypo
induced a significant switch of recipient macrophages toward an
anti-inflammatory phenotype (CD206: p< .0001; CD51:
p 5 .0126; CD36: p 5 .0027) (Fig. 3D, 3E). It is noteworthy that
EVs that were released under hypoxic conditions exerted a
strengthened anti-inflammatory effect compared to EVs released
under normoxia, downregulating the expression of the co-
stimulatory molecule CD86 and the activation marker CD11b
(p 5 .0095 and p 5 .0448, respectively) (Fig. 3E). Taken together,
these data indicate that MSC-derived EVs, and in particular those
released under hypoxic conditions, actively interact with key
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Figure 1. MSC-derived EV characterization. (A): Transmission electron microscopy analysis of MSC cultured for 48 hours in normoxic and
hypoxic conditions and corresponding isolated EVNormo and EVHypo. Scale bars: MSC panels5 500 nm; EV panels5 100 nm. (B): Representa-
tive Western blot analysis for EV specific markers (CD81 and Alix) and for b-Tubulin. (C): Flow cytometry strategy adopted to characterize
EVNormo and EVHypo. Vesicles were stained by the lipophilic dye Cell Trace, the vesicular marker CD63 and the MSC marker CD105. (D): Histo-
gram showing the percentage of Cell Tracepos EVs coexpressing CD63 or CD105. Data are presented as mean6 SD. ###, p 5 .0003 (unpaired
Student’s t test). (E): Histogram showing the absolute number of Cell Tracepos EVs quantified trough Trucount fluorescent beads. Data are pre-
sented as mean6 SD. #, p 5 .0318 (unpaired Student’s t test). (F): Representative photo of Matrigel plugs in combination with PBS (Ctrl), 5 lg of
EVNormo or 5 lg of EVHypo, recovered 3 weeks after their in vivo injection. (G): Histograms summarizing densitometric analysis of PCR products nor-
malized to the housekeeping gene Hprt. Pecam1; VegfA. (H): Representative histology of Matrigel plug sections stained for hematoxylin and eosin
(upper panels) and for the endothelial cell marker CD31 (lower panels). Magnification 340. Scale bar5 100 lm. Abbreviations: EVs, extracellular
vesicles; FSC, forward scatter channels; Hprt, hypoxanthine guanine phosphoribosyltransferase; MSCs, mesenchymal stem cells; Pecam1, platelet and
endothelial cell adhesion molecule 1; SSC, side scatter channels; VegfA, vascular endothelial growth factor A.
components of the innate immune system and influence their
immunoregulatory and regenerative behavior.
EVs Regulate the M1/M2 Balance of Infiltrating
Macrophages in a Skeletal Muscle Injury Model In Vivo
Skeletal muscle has a remarkable capacity for regeneration
through a complex injury/repair process that includes
inflammation, myofiber regeneration, and angiogenesis [31, 32].
Observations that different M/ subsets are associated with differ-
ent stages of muscle regeneration led us to investigate whether
EV treatment could influence macrophage polarization from M1
to M2 phenotype in vivo. We opted for a CTX injury in the mouse
TA muscle, a reproducible model that recapitulates all healing
phases. Muscles, subjected to CTX-damage followed by injection
Figure 2. Analysis of miRNAs enriched in EVHypo. (A): Scatter plot of the human miRNome miScript miRNA PCR Array profile depicting the
distribution of differentially expressed miRNAs in EVHypo versus EVNormo. The graph was obtained by plotting the normalized log10 miRNA
expression (22DCt) in EVHypo (y-axis) divided by the one in the control EVNormo (x-axis). Red and green dots represent upregulated and down-
regulated miRNAs with an expression level >2 or< 0.5, respectively. (B): Histografic representation of under-expressed (green) and over-
expressed (red) miRNAs isolated in EVHypo. (C–F): Validation of selected miRNAs expressed by EVNormo and EVHypo through quantitative real-
time PCR. Normalized data were averaged from three independent experiments, and expressed as mean6 SD. (C): miR-223, *, p 5 .0274;
(D): miR146b, **, p 5 .0062; (E): miR-126, **, p 5 .0038; (F) miR-199a, *, p 5 .0264 (unpaired Student’s t test). Abbreviation: EVs, extracellu-
lar vesicles.
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Figure 3. MSC-derived EVs trigger macrophage (M/) proliferation and polarization. (A): Immunofluorescence analysis of MU cocultured for
3 hours in a serum-free (SF) medium without EVs (Ctrl w/o EV), and with either normoxic or hypoxic PKH67-labeled EVs (EVNormo and EVHypo).
DAPI (blue), b-tubulin (red), PKH67 (green). Magnification 363. Scale bar 520 lm. (B): Flow cytometry analysis of MU cocultured for 3 hours
without EVs (gray line) and with normoxic (light blue line) and hypoxic (green line) PHK67-labeled EVs. (C): Proliferation inductive effect of
EVNormo and EVHypo on MU following 24 hour incubation with 10 lM BrdU, compared to the control (MU w/o EV). The average of three inde-
pendent experiments is shown. Statistical significance was determined using ANOVA (**, p 5 .0031; ****, p< .0001) and unpaired Student’s
t test to compare EVNormo versus EVHypo (##, p 5 .0011). (D) Representative dot plots of phenotypic characterization of MU cultured for 72
hours in SF standard medium (MU w/o EV, gray line), and in SF medium containing 1 lg of EVNormo (MU 1 EVNormo, light blue line) and EVHypo
(MU 1 EVHypo, green line). Ly6C , CD11b, CD40, and CD86 were selected as markers of pro-inflammatory MU (M1); CD36, CD51, CD206 as
markers of anti-inflammatory MU (M2). (E): Histogram presenting the data already shown in panel (D) as relative mean fluorescent intensity.
In gray are indicated selected M1 markers and in purple M2 markers. Each column is the average of three independent experiments. Statisti-
cal significance was determined using an unpaired Student’s t test. #, p 5 .0448; ##, p 5.0095. Abbreviations: DAPI, 4’,6-diamidino-2-phenyl-
indole; FITC, Fluorescein isothiocyanate; EVs, extracellular vesicles.
of either EVNormo or EVHypo, were examined at different times (Fig.
4A). One day after CTX injection, the histopathological evaluation
of muscle damage was performed in all experimental groups. Nor-
mal myofibers with uniform size, poligonal shape and peripheral
nuclei were observed in untreated mice (naive) (Fig. 4B). Follow-
ing injury, CTX-treated mice, as well as EVNormo and EVHypo treated
animals, had extensive necrotic muscle fibers with vigorous mono-
nuclear cell infiltrate (Fig. 4B). However, at day 1 and 2 post-lesion
induction, the ratio between IL6 and IL10 cytokines (IL6/IL10) pro-
gressively decreased in EV-treated muscles compared to CTX-
treated controls (day1: p 5 .0024; day 2: p< .0001), thus indicat-
ing that the injection of both types of EVs significantly mitigated
the inflammatory milieu within the injured tissues (Fig. 4C). At day
2, this observation was accompanied by a significant increase in
both types of EV-treated muscles of the M2 markers Arginase 1
(Arg1) and Chitinase 3-like 3 (Ym1) (p 5 .0453 and p 5 .0087,
respectively), parallel to a decreased expression of the M1 marker
Nitric Oxide Synthase 2 (Nos2) (Fig. 4D–4F). The latter results were
also confirmed by flow cytometry, analyzing the cells recovered
from the damaged and/or EV-treated muscles. The percentage of
CD206-positive (CD206pos) M/ compared to the percentage of
Ly6C-positive (Ly6Cpos) cells was significantly higher within the
cells recovered from EVHypo-treated muscles compared to both
CTX-treated and EVNormo-treated samples (p 5 .0006) (Fig. 4G).
Given the important role of M/ in muscle regenerative activities,
chemokines that are known to attract and interact with these
innate immune cells play pivotal roles in the process of muscle
recovery after an injury. Among the others, monocyte chemoat-
tractant protein-1 (MCP-1) coordinates inflammation-dependent
events involved in muscle regeneration [33]. Interestingly, at day 2
post-lesion induction, the expression level of MCP-1 was signifi-
cantly upregulated in EVHypo-treated muscles compared to other
experimental conditions (p 5 .028) (Supporting Information Fig.
2A). Since CTX-induced skeletal muscle injury is an optimal model
of muscle self-repair, we analyzed key genes playing a dominant
role during the overlapping regeneration and remodeling phases
that follow inflammation. At day 7, when compared to CTX-
treated and EVNormo-treated muscles, EVHypo-treated muscles pre-
sented a significant upregulation of both Paired Domain Transcrip-
tion Factor 7 (Pax7) and Myogenic Differentiation Antigen (MyoD)
genes, selectively expressed by activated satellite cells (p 5 .048
and p 5 .0006, respectively), as well as of embryonic myosin
heavy chain (eMyhc), expressed by regenerating fibers (p 5 .018)
(Supporting Information Fig. 2B). Concurrently, the progression of
muscle regeneration and the prospective differences between EV-
treated and CTX-treated muscles were confirmed by histological
observations. As expected, many newly formed centrally
nucleated fibers were present in CTX-treated muscles (Supporting
Information Fig. 2C). It’s well known that multinucleated muscle
fibers form from the fusion of mononucleated myoblasts [34].We
observed that the number of mononucleated myoblasts was sig-
nificantly decreased in both types of EV-treated muscles, com-
pared to the CTX controls (Supporting Information Fig. 2C–2E,
2G). Interestingly, in the same EV-treated muscles the number of
fibers containing two or more centrally located nuclei was signifi-
cantly increased compared to the CTX-injured muscles, and this
increase was greater followed EVHypo injection (Supporting Infor-
mation Fig. 2C, 2D, 2F, 2G). These results suggest that MSC-
derived EVs, and in particular those released under hypoxic condi-
tions, accelerate the muscle regeneration process.
DISCUSSION
EVs represent novel players in various cell communication sys-
tems, being involved in the regulation of many routes of signaling
pathways and intercellular information transfer [35]. It is thanks
to their vast amount of properties that EVs have been successfully
applied in different fields, such as tumor biology, immunology and
regenerative medicine [36].
Stem/progenitor cells and in particular MSCs are active biolog-
ical components of many regenerative medicine therapies [37].
Recent efforts in elucidating mechanisms of action of these thera-
pies have revealed an increasingly important role of the cell para-
crine activity in enhancing positive outcomes without a significant
cell engraftment [13, 38].We recently demonstrated a new role of
MSCs in wound healing, showing that they can act as modulators
of the inflammatory response, secreting cytokines and factors
able to induce the switch of pro-inflammatory macrophages
toward a pro-resolving, anti-inflammatory phenotype [10].
Indeed, the initial inflammation underlying all regenerative proc-
esses is finely coordinated to obtain an efficient outcome, and an
altered identity of the inflammatory infiltrate can result in a per-
sistent rather than resolved inflammatory phase [39]. Macro-
phages, that are an essential component of the inflammatory
infiltrate, play important roles in the maintenance of tissue home-
ostasis [40]. In response to different signals, macrophages are sub-
jected to a reprogramming and undergo two different polarization
states that mirror the Th1/Th2 nomenclature [41]. Classical acti-
vated M1 macrophages, induced by interferon-g alone or in com-
bination with microbial stimuli and/or inflammatory cytokines,
exert pro-inflammatory activities. On the contrary, cytokines such
as IL-4 and IL-13 induce an alternative activation of M2 macro-
phages, which become involved in inflammation resolution [42].
Since secreted vesicles represent a relevant component of the
MSC regenerative milieu [43], in the present study we investi-
gated the possible role of EVs in modulating the MSC paracrine
capacity to actively interact with innate immune cells. Given that
the presence of areas of hypoxia is a prominent feature of various
inflamed, diseased tissues contributing to modulate the MSC
regenerative milieu, these interactions were evaluated after both
normoxic and hypoxic cell conditioning [44]. We showed that: (a)
hypoxic conditioning induced an increased secretion of EVs by
MSCs, enriching the EV content in microRNAs involved in different
phases of the healing process; (b) MSC-EVs acted as “switchers”
of macrophage polarization toward an anti-inflammatory pheno-
type. The latter result was observed both in vitro and in vivo in a
mouse model of skeletal muscle regeneration. Literature reports
indicate that hypoxia conditioning of MSCs regulates the cargo
and protein packaging into EVs [45]. As herein shown, the higher
expression of both pro-angiogenic factors and specific microRNAs,
such as miR-223, miR-146b, miR126, and miR-199a in response to
hypoxia could be at least in part due to a higher number of EVs
released by MSCs. Among microRNAs carried by EVs, miR-223 rep-
resents a novel regulator of macrophage polarization, being
responsible of suppressing classic pro-inflammatory pathways and
enhancing the alternative anti-inflammatory responses, whereas
the enforced expression of mir-146b in human monocytes leads
to a significant reduction in the production of several pro-
inflammatory cytokines and chemokines, such as IL6 [25]. In addi-
tion, the increased expression pattern of miR-126 and miR-199a
plays important roles in the repair process restoring vascular
integrity and inducing cell differentiation, respectively [27, 28].
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Figure 4. MSC-derived EVs play direct effects on M1/M2 balance in a mouse model of cardiotoxin-induced injury. (A): Schematic diagram of
the experimental plan, illustrating the timelines of tibialis anterior (TA) muscle examination after CTX-injury and EV-injection. (B): Representa-
tive hematoxylin and eosin (H&E) staining of TA muscles derived from naive C57Bl/6 mouse, CTX-treated mouse (upper left and upper right
panels, respectively), and from EVNormo- and EVHypo-treated mice (bottom left and bottom right panels, respectively), one day after damage
induction. Magnification 320. Scale bar5 100 lm. (C): Quantitative real-time PCR analysis of pro-inflammatory (IL6) and anti-inflammatory
(IL10) cytokynes in TA muscles derived from mice treated with CTX (gray) alone or in combination with 1 lg EVNormo (light blue) or EVHypo
(green), at 1 and 2 days post-damage induction. Data are presented as log2 of mean expression ratio6 SEM. Statistical significance was
determined using ANOVA. 88, p 5 .0024; 8888, p< .0001. (D–F): Quantitative RT-PCR for selected M1 (Nos2) and M2 (Arg1, Ym1) markers in
CTX (gray), EVNormo (light blue) and EVHypo (green), at 1 and 2 days post-CTX injury. B2m has been used as a housekeeping gene. Data are
shown as mean6 SEM. Statistical significance was determined using ANOVA and Tukey’s multiple comparisons test; (D) *, p 5 .0453. (E) *,
p 5 .0087. (G): Flow cytometry analysis of MU subtypes recovered in the treated TA muscles (CTX, EVNormo and EVHypo) after 2 days. Data are
presented as mean expression ratio between CD206 (M2) and Ly6C (M1). 888, p 5 .0006 (ANOVA). Abbreviations: Arg1, Arginase 1; CTX, cardi-
otoxin; EVs, extracellular vesicles; Nos2, nitric oxide synthase 2.
An increasing number of literature reports indicate that MSCs
possess the capacity to reduce inflammation and to promote tis-
sue repair processes by their paracrine activity [13, 46]. In particu-
lar, it was recently reported that lipopolysaccharide
preconditioning of umbilical cord-MSCs increased the secretion of
exosomes, responsible for the switch of macrophages to a M2-like
profile [47]. In line with this evidence, we here demonstrated for
the first time that adipose tissue derived-MSCs release EVs
endowed with potent anti-inflammatory capacities to balance
macrophage polarization toward a M2 profile, especially after
hypoxic pre-treatment. The in vitro stimulation of GM-CSF treated
macrophages with either EVNormo or EVHypo led responding cells to
increase their proliferation rate and progressively acquire a M2
phenotype characterized by the expression of CD206, CD51, and
CD36. The proper requirement for macrophages is a key feature
for efficient muscle regeneration [31, 32]. Indeed, macrophages
exert specific functions all through the inflammatory response fol-
lowing muscle damage, which includes the sequential release of
pro-inflammatory effectors, the phenotype shift and the activa-
tion of myogenic precursors [33]. In this context, CTX-induced skel-
etal muscle damage represents a highly reproducible model
useful to study each step of the inflammatory cascade. The
expression level of the typical pro-inflammatory, Th-1 cytokine IL6
was significantly downregulated in EV-treated muscles at day 1
and 2 post-lesion induction, that represents the timeframe in
which maximum macrophage infiltration occurs [48]. This was
strictly associated with a significant upregulation of IL10, a cyto-
kine that contributes to promote an anti-inflammatory microen-
vironment [49]. At the same times, the dynamics of macrophage
activation marker expression in response to EV administration
were investigated. At day 2 the early marker of innate and classical
activation Nos2 was downregulated whereas the expression of
Arg1 and Ym1, late markers of alternative activation, were upregu-
lated. This effect was even greater following EVHypo administra-
tion. In the EV-treated muscles, the changes in the expression of
these early/late markers coincided with an increased percentage
of CD206pos macrophages. MCP-1, also known as CCL2, is impor-
tant in macrophage recruitment and activation. Mice deficient in
CCL2/MCP1 show impaired muscle regeneration, characterized by
a decrease in the diameter of the new myofibers, a reduced num-
ber of capillaries, and fat accumulation [50]. In our experimental
setting, the administration of hypoxic vesicles determined, at day
2, an accumulation of MCP-1 parallel to the macrophage shift
toward a M2 phenotype. These concomitant events could under-
lie the increased expression, at day 7, of the myogenic markers
Pax7 and MyoD, that are upregulated and activated by satellite
cells, the increased expression of eMyhc, that is upregulated by
regenerating myofibers, as well as the significantly increased num-
ber of newly formed multinucleated muscle fibers, thus indicating
an acceleration of tissue repair triggered by EV administration.
When developing novel regenerative medicine strategies, the
rational control of inflammation represents a critical aspect to
consider. In this context, the anti-inflammatory, pro-regenerative
effects mediated by MSC-EVs could be exploited for therapeutic
purposes. From a translational perspective, the use of EVs, in
comparison to either traditional cell-based therapies or more
recent cell-free strategies based on the use of MSC secretome,
presents undeniable advantages. Compared with traditional cell-
based therapies, the benefits underlying the use of EVs arise in the
possibility to develop safer cell-free therapeutic approaches that
could overcome the regulatory obstacles and clinical risks associated
to the use of transplanted progenitor cells. Compared to the use of
poorly characterized soluble factors, the advantage relies on the abil-
ity of EVs to interact and reprogram the surrounding microenviron-
ment, which is a consequence of the variety of their cargo, therefore
influencingmany biological processes, in particular in injured tissues.
CONCLUSION
This study demonstrates that MSCs cultured under both normoxic
and hypoxic conditions release EVs endowed with anti-
inflammatory effects. When co-cultured with responding BM-
derived macrophages, EVs are efficiently internalized by respond-
ing cells, inducing, in the short term, an increase in their prolifera-
tion rate, and shifting the balance toward a M2 pro-resolving
phenotype. A significant enrichment in microRNAs involved in dif-
ferent phases of the healing process was detectable in EVs espe-
cially in the ones derived from hypoxia conditioned MSCs. Direct
administration of EVs in a CTX-induced skeletal muscle injury
reduced the inflammatory response, upregulating key markers of
alternative activation patterns, and accelerating the expression of
myogenic markers. These effects were even greater following
EVHypo administration. Although additional investigations on the
mechanisms underlying the therapeutic effects of MSC-EVs is still
necessary before proceeding with clinical trials, these results
already provide the basis for the use of EVs as an alternative cell-
free approach for the induction of regenerative processes.
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